David Rosenthal, MD
Assistant Professor of Medicine (General Medicine)Cards
About
Research
Publications
2025
Advanced External Beam Stereotactic Radiotherapy for Skull Base Reirradiation
Wang H, Alsanea F, Rhee D, Zhang X, Liu W, Yang J, Wen Z, Zhao Y, Williamson T, Hunter R, Balter P, Briere T, Zhu R, Lee A, Moreno A, Reddy J, Garden A, Rosenthal D, Gunn G, Phan J. Advanced External Beam Stereotactic Radiotherapy for Skull Base Reirradiation. Cancers 2025, 17: 540. PMID: 39941906, PMCID: PMC11817895, DOI: 10.3390/cancers17030540.Peer-Reviewed Original ResearchIntensity-modulated proton therapyVolumetric-modulated arc therapyStereotactic body radiation therapyGK plansIntensity‐modulated proton therapy plansStereotactic body radiation therapy plansModern treatment planning systemsTreatment plan qualityTreatment planning systemDose fall-offVarian TrueBeam STxSteep dose gradientsProton therapy machineExternal beam radiotherapy modalityLow-dose regionRadiation delivery systemsCK plansIMPT plansTrueBeam STxAdjacent critical structuresDose gradientArc therapyConformal doseDose spreadTarget coverageDetection of alteration in carotid artery volumetry using standard-of-care computed tomography surveillance scans following unilateral radiation therapy for early-stage tonsillar squamous cell carcinoma survivors: a cross-sectional internally-matched carotid isodose analysis
Koutroumpakis E, Naser M, Mohamed A, Eraj S, Jarre A, Shiao J, Kamal M, Perni S, Phan J, Morrison W, Frank S, Gunn G, Garden A, Deswal A, Abe J, Rosenthal D, Mouhayar E, Fuller C. Detection of alteration in carotid artery volumetry using standard-of-care computed tomography surveillance scans following unilateral radiation therapy for early-stage tonsillar squamous cell carcinoma survivors: a cross-sectional internally-matched carotid isodose analysis. Clinical And Translational Radiation Oncology 2025, 51: 100912. PMID: 39867727, PMCID: PMC11762641, DOI: 10.1016/j.ctro.2025.100912.Peer-Reviewed Original ResearchPost-RT CT scansCT scanTonsillar cancerPatients treated with definitive surgeryDose rangeContrast-enhanced CT scanCarotid arteryCT scans of patientsIrradiated carotid arteriesUnilateral radiation therapySignificant dose-response trendSurveillance CT scansTreated with intensityNo significant dose-response trendScans of patientsDose-response effectDose-response trendDose-response relationshipStatistically significant differenceUnilateral radiotherapyConcurrent chemoradiationInduction chemotherapyIsodose lineRadiation therapyDefinitive surgery
2024
Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer
Bronk J, Augustyn A, Mohamed A, Fuller C, Garden A, Moreno A, Lee A, Morrison W, Phan J, Reddy J, Rosenthal D, Spiotto M, Frank S, Dadu R, Busaidy N, Zafereo M, Wang J, Maniakas A, Ferrarotto R, Iyer P, Cabanillas M, Gunn G. Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer. Radiotherapy And Oncology 2024, 202: 110602. PMID: 39489425, PMCID: PMC11720968, DOI: 10.1016/j.radonc.2024.110602.Peer-Reviewed Original ResearchIntensity modulated radiation therapyLoco-regional progressionAnaplastic thyroid cancerTarget volumeConcurrent chemotherapyRadiation therapyThyroid cancerHigh dosesAreas of gross diseaseMedian progression free survivalMedian IMRT doseGross tumor volumeMedian overall survivalProgression free survivalNeo-adjuvant strategiesDeformable image registrationIntensive treatment scheduleLevels II-VDiagnostic CTsIMRT dosePlanning CTsGross diseaseLocoregional diseaseUnresectable diseaseFree survivalMetrics Derived from Architecture of Tumor-Infiltrating Lymphocytes are Associated with Overall Survival in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Patients: Results from NRG/RTOG 0129 and 0522
Corredor G, Harris J, Koyuncu C, Pathak T, Pandav K, Toro P, Yang K, Faraji F, Castro P, Sandulache V, Koyfman S, Nguyen F, Garden A, Caudell J, Jones C, Rosenthal D, Le Q, Lewis J, Madabhushi A. Metrics Derived from Architecture of Tumor-Infiltrating Lymphocytes are Associated with Overall Survival in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Patients: Results from NRG/RTOG 0129 and 0522. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s130. DOI: 10.1016/j.ijrobp.2024.07.236.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesDisease-free survivalOverall survivalHazard ratioHPV+ OPSCCPoor survivalRisk of disease-free survivalOropharyngeal squamous cell carcinoma patientsDisease-free survival modelsSquamous cell carcinoma patientsTreated with standard therapyRisk of overall survivalAssociated with overall survivalHigh-risk ptsRisk scoreCell carcinoma patientsRisk of poor survivalSubsets of patientsCox regression modelsLow-risk counterpartsHPV-positivePrimary tumorCarcinoma patientsStandard therapyInstitutional cohortAssociation of Biologically Effective Dose and Survival in Patients Receiving Head and Neck Stereotactic Body Radiation Therapy
Márquez C, Phan J, Lee A, Reddy J, Garden A, Gunn G, Frank S, Fuller C, Moreno A, Morrison W, Rosenthal D, Spiotto M. Association of Biologically Effective Dose and Survival in Patients Receiving Head and Neck Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e770-e771. DOI: 10.1016/j.ijrobp.2024.07.1694.Peer-Reviewed Original ResearchStereotactic body radiation therapyHead and neck cancerBiologically effective doseRadiation therapyPerformance statusN stagePatients treated with stereotactic body radiation therapyTreat recurrent head and neck cancerPatients treated with initial surgeryRecurrent head and neck cancerHigher biologically effective dosesIncreasing BEDMedian follow-up durationAssociated with improved survivalHead and neck cancer patientsEffective doseNo survival improvementSurgically resected patientsNational Cancer DatabaseFractionation schemeAssociated with enhanced survivalCox regression modelsDose escalationHPV statusResected patientsA Lymph Node Immune Score (LNIS) Identifies Prognostic Immune Phenotypes Shared across Head and Neck Cancers
Karpinets T, Garden A, Rosenthal D, Fuller C, Frank S, Gunn G, Phan J, Morrison W, Lee A, Moreno A, Song X, Mitani Y, Ferrarotto R, Gross N, Zhang J, Myers J, El-Naggar A, Spiotto M. A Lymph Node Immune Score (LNIS) Identifies Prognostic Immune Phenotypes Shared across Head and Neck Cancers. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s222-s223. DOI: 10.1016/j.ijrobp.2024.07.2308.Peer-Reviewed Original ResearchHead and neck squamous cell cancerNon-small cell lung cancerLymph node metastasisPrognostic gene signatureRelapse free survivalExtranodal extensionFree survivalGene signatureImmune microenvironmentImmune scoreLymph nodesImmune phenotypeRejection subtypeHPV-positive HNSCCImmune rejectionAbsence of extranodal extensionNon-small cell lung cancer cohortsHPV-negative HNSCC patientsUnivariate Cox proportional hazards modelHead and neck cancerImmunology-related genesMetastatic lymph nodesLymph node microenvironmentSquamous cell cancerCell lung cancerMulticenter Phase III Trial of Chemoradiation (CRT) with IMPT vs. IMRT for Oropharyngeal Squamous Cell Carcinoma (OPSCC): Secondary Analysis of Association of Lymphopenia with Treatment Modality, Emergency Room (ER) Visits and Hospital Admission (HA)
Grippin A, Foote R, Busse P, Rosenthal D, Hernandez M, Garden A, Sturgis E, Ferrarotto R, Gunn G, Patel S, Lee N, Lin A, Snider J, McDonald M, Henson C, Bajaj G, Kalman N, Parvathaneni U, Frank S. Multicenter Phase III Trial of Chemoradiation (CRT) with IMPT vs. IMRT for Oropharyngeal Squamous Cell Carcinoma (OPSCC): Secondary Analysis of Association of Lymphopenia with Treatment Modality, Emergency Room (ER) Visits and Hospital Admission (HA). International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e755. DOI: 10.1016/j.ijrobp.2024.07.1658.Peer-Reviewed Original ResearchIntensity modulated proton therapyOropharyngeal squamous cell carcinomaAbsolute lymphocyte countAbsolute lymphocyte count nadirBaseline absolute lymphocyte countGrade 4 lymphopeniaMultivariate analysisTreatment modalitiesHospital admissionAdvanced stage oropharyngeal squamous cell carcinomaStage oropharyngeal squamous cell carcinomaMulticenter phase III trialPhase III randomized controlled trialsEmergency roomPhase III non-inferiority trialAssociation of lymphopeniaBilateral neck radiationBody mean doseStage III-IVAEffectiveness of treatment modalitiesSquamous cell carcinomaAssociated with increased ratesClinical implicationsER visitsSecondary analysisThe Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Wang L, Zhang Y, Ausat N, Hernandez M, Rosenthal D, Garden A, Ferrarotto R, Gunn G, Fuller C, Phan J, Morrison W, Lee A, Moreno A, Gross N, Spiotto M, Frank S. The Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamous Cell Carcinoma (OPSCC). International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s123-s124. DOI: 10.1016/j.ijrobp.2024.07.223.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaIntensity modulated proton therapyDNA scoreConcurrent chemoradiationTreatment failureNode dissectionInduction chemotherapyHuman papillomavirusHPV+ oropharyngeal squamous cell carcinomaHigh risk of treatment failurePhase III randomized trialRisk of treatment failureMulticenter phase III randomized trialPost-induction chemotherapyTreatment de-escalationHuman papillomavirus DNALymph node dissectionPhase III trialsSquamous cell carcinomaPotential of TFAJCC-7RT doseTumor controlTreatment toxicityPost-RT19 Development of SO-HNC, An Extensible Staging Ontology for Head and Neck Cancer
Arifin A, Myers J, Ferrarotto R, Johnson F, Lango M, Rosenthal D, Fuller C, Tao C, Moreno A. 19 Development of SO-HNC, An Extensible Staging Ontology for Head and Neck Cancer. Radiotherapy And Oncology 2024, 198: s11-s12. DOI: 10.1016/s0167-8140(24)03675-2.Peer-Reviewed Original ResearchA prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma
Goodman C, DeMonte F, Nguyen T, Garden A, Wang C, Wang X, Diao K, Lee A, Reddy J, Moreno A, Spiotto M, Fuller C, Rosenthal D, Ferrarotto R, Raza S, Su S, Warner A, Hanna E, Phan J. A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma. Head & Neck 2024, 47: 81-89. PMID: 39073252, PMCID: PMC11729999, DOI: 10.1002/hed.27887.Peer-Reviewed Original ResearchStereotactic body radiotherapyOlfactory neuroblastomaOutcomes of stereotactic body radiotherapyTreated with stereotactic body radiotherapyTwo-year local controlHigher local control rateONB patientsPatient-reported quality of lifeLocal control rateProspective cohort studyPatient-reported qualityBrain radionecrosisStereotactic radiotherapyMedian doseTumor controlDural lesionsProspective registryRadiographic progressionControl rateMinimal toxicityCohort studyLocal controlQuality of lifePatientsRecurrence
Academic Achievements & Community Involvement
Clinical Care
Overview
David Rosenthal, MD, is a primary care physician who specializes in general internal medicine. He focuses on providing comprehensive health care services, especially to populations such as veterans experiencing homelessness.
As an associate professor at Yale School of Medicine, Dr. Rosenthal’s research interests include health care services for vulnerable populations and health informatics, aiming to improve accessibility and efficacy of care for all. He has developed and implemented innovative technology solutions to enhance patient care, including mobile apps for substance use disorder management.
Dr. Rosenthal received his medical training from Northwestern University Feinberg School of Medicine, followed by an internship and primary care residency at Brigham and Women's Hospital. He has been recognized by the Aspen Institute as a Health Innovator Fellow for his contributions to public health and innovation.
Clinical Specialties
News & Links
News
- March 11, 2025
Yale Department of Internal Medicine Faculty Promotions and Appointments (March 2025)
- January 15, 2025
Student Auction Supports New Haven Nonprofits
- July 08, 2024
Dean Ranney Joins Other Public Health Thought Leaders at Aspen Ideas: Health Festival
- December 19, 2023
A Night of Fun Raises Money to Help Fight Hunger and Homelessness
Get In Touch
Contacts
General Internal Medicine
150 Sargent Dr
New Haven, CT 06511
United States